Based on phase 1 and 2 trial results and pooled safety data from several clinical trials, zanubrutinib moves forward with a priority review in relapsed/refractory marginal zone lymphoma.
The approval of umbralisib was primarily based on data from the marginal zone lymphoma and follicular lymphoma patient cohorts of the phase 2b UNITY-NHL trial.
A 70-year-old woman developed red-to-violaceous papules, plaques, and nodule- like skin lesions several months prior to her presentation. The skin lesions mostly involved her lower neck and abdominal area. What is the most likely diagnosis?